Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stoke Therapeutics, Inc.

10.88
-0.0600-0.55%
Volume:372.31K
Turnover:4.04M
Market Cap:594.01M
PE:12.41
High:11.00
Open:10.89
Low:10.64
Close:10.94
Loading ...

Chief Medical Officer Barry Ticho Reports Disposal of Common Shares of Stoke Therapeutics Inc

Reuters
·
Yesterday

Stoke Therapeutics Inc. Conducted Annual Meeting of Stockholders

Reuters
·
Yesterday

Stoke Therapeutics Inc. to Present at Jefferies Global Healthcare Conference

Reuters
·
29 May

Stoke Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $35 From $47

THOMSON REUTERS
·
14 May

Stoke Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BRIEF-Stoke Therapeutics Q1 Operating Income USD 111.24 Million

Reuters
·
13 May

Stoke Therapeutics Q1 EPS $1.90 Beats $(0.42) Estimate, Sales $158.57M Beat $7.61M Estimate

Benzinga
·
13 May

Stoke Therapeutics Initiates Phase 3 Trial for Zorevunersen, Aiming to Launch First Disease-Modifying Treatment for Dravet Syndrome by Mid-2028

Reuters
·
13 May

Stoke Therapeutics Inc. Reports Q1 2025 Results: No Significant Changes in Sales, Revenue, or EPS Noted

Reuters
·
13 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stoke Therapeutics (STOK), Novavax (NVAX) and McKesson (MCK)

TIPRANKS
·
09 May

Stoke Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
02 May

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks
·
01 May

Is There An Opportunity With Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 49% Undervaluation?

Simply Wall St.
·
24 Apr

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
23 Apr

Stoke Therapeutics remains significantly undervalued, says Canaccord

TIPRANKS
·
31 Mar

Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.
·
22 Mar

Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham

Dow Jones
·
19 Mar

Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named

MT Newswires Live
·
18 Mar

Stoke Therapeutics Chief Executive Edward Kaye Stepping Down

Dow Jones
·
18 Mar

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Business Wire
·
18 Mar